Senti Biosciences Inc. (SNTI)
Company Description
Senti Biosciences, Inc. operates as a gene circuit company.
The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments.
Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications.
The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC).
It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body.
The company was founded in 2016 and is based in South San Francisco, California.

Country | United States |
IPO Date | May 26, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 34 |
CEO | Dr. Timothy K. Lu M.D., Ph.D. |
Contact Details
Address: 2 Corporate Drive South San Francisco, California United States | |
Website | https://www.sentibio.com |
Stock Details
Ticker Symbol | SNTI |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001854270 |
CUSIP Number | 81726A100 |
ISIN Number | US81726A1007 |
Employer ID | 86-2437900 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Timothy K. Lu M.D., Ph.D. | Co-Founder, Chief Executive Officer & Director |
Dr. James J. Collins Ph.D. | Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director |
Dr. Kanya Rajangam M.D., Ph.D. | President, Head of Research & Development and Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 31, 2025 | 424B5 | Filing |
Mar 24, 2025 | 8-K | Current Report |
Mar 21, 2025 | S-3 | Filing |
Mar 21, 2025 | S-3 | Filing |
Mar 20, 2025 | 10-K | Annual Report |
Mar 20, 2025 | 8-K | Current Report |
Mar 17, 2025 | SCHEDULE 13D | Filing |
Mar 17, 2025 | SCHEDULE 13D/A | [Amend] Filing |
Mar 14, 2025 | 4 | Filing |
Mar 13, 2025 | 3 | Filing |